Zamtocabtagene autoleucel

N/A

Report date: 2026/05/08 20:02:52

Base Information

Drug NameZamtocabtagene autoleucel
Drug Alias NameAnti-CD2019 CAR T cell therapyCD2019-targeting CAR T cell therapyCD20/CD19 bispecific CAR T-cell therapyDual anti-CD19/anti-CD20 CAR T-cell therapyCD20-CD19-targeting CAR T Cells +[8] 
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy +[4] 
Mechanisms of ActionT lymphocyte replacementsAnti-CD19Anti-CD20
TargetsB-lymphocyte antigen CD19B-lymphocyte antigen CD20
Therapy Area/IndicationsCentral Nervous System LymphomaRichter's SyndromeScleroderma, Diffuse +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[16] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMiltenyi Biotec
China Registration ClassN/A

Develop Information

Active CompaniesMiltenyi Biomedicine Gmbh
Inactive CompaniesN/A
Active IndicationsCentral Nervous System LymphomaRichter's SyndromeScleroderma, Diffuse +[10] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A